NEW YORK, Nov. 24, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, is scheduled to present at the LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014. The conference will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California.
The presentation is scheduled for 8:30 a.m. PST/11:30 a.m. EST and will be available as a live and archived webcast. The replay will be available for 90 days following the live broadcast. Interested parties may access the webcast from the Relmada website, http://www.relmada.com.
Mr. Traversa and other members of the management team will be available for one-on-one meetings at the conference. Members of the investment community who are interested in meeting with management should contact Michael Becker, senior vice president of finance and corporate development at Relmada Therapeutics, Inc., via telephone at (212) 702-7169 or e-mail at [email protected].
About LD MICRO
LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm hosts the LD MICRO "Main Event" Micro-Cap Growth Conference for investors in December of each year. This year's conference will feature presentations by over 240 publicly traded companies and is expected to attract more than 1,000 attendees. For additional information, please visit the LD Micro conference website at http://www.ldmicro.com.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-ld-micro-conference-300000054.html
SOURCE Relmada Therapeutics, Inc.